Identifying Disease-Related Variants, Monogenic Disorders, and Repeat Expansion Disorders
Identification of Disease-Related Genetic Variants

Genome-Wide Approaches:
Genome-Wide Association Studies (): Compares allele frequencies in large case-control cohorts using microarrays to identify common susceptibility variants (). Requires functional biological validation.
Whole Genome Sequencing (): Direct determination of an individual's complete genome sequence to identify single-nucleotide variants (), insertions/deletions (), copy number variants (), and structural variants (). Main bottleneck is variant filtering and prioritization.
Human Genome Variation Overview:

Non-variable Portion: Comprises ∼99.6% of the diploid genome (∼5,973,000,000 base pairs).
Single-Nucleotide Variants (SNVs): Most common by count (∼5,000,000 per genome; ∼0.08% base coverage).
Insertions and Deletions (Indels): ∼600,000 variants per genome (∼0.03% base coverage).
Structural Variants (SVs / CNVs): Least common by count (∼25,000 per genome), but affect the greatest total base coverage (>20,000,000 nucleotides).
Monogenic Disorders and Case Study: Cystic Fibrosis
Monogenic Disorders: Caused by pathogenic variants in a single locus. Can be inherited or de novo, with variable penetrance, severity, and age of onset.
Cystic Fibrosis ():

Inheritance & Gene: Autosomal recessive disorder caused by loss-of-function variants in both alleles of CFTR (encodes an ATP-binding cassette Cl− and HCO3− ion channel on apical membranes).
Pathophysiology: Loss of transport creates an osmotic deficit, causing abnormally thick mucus obstructing airways, pancreatic ducts, and other epithelia. Symptoms include recurrent lung infections, exocrine pancreatic insufficiency, failure to thrive, and elevated sweat chloride.
Most Common Variant (F508del / c.1521_1523delCTT): Accounts for ∼66.8% of alleles worldwide. In-frame deletion of phenylalanine at position 508 causes protein misfolding, endoplasmic reticulum retention, and proteasomal degradation.

- **Functional Classes**:

- **Class I**: No protein synthesis (e.g., ).
- **Class II**: Block in processing/maturation & proteasomal degradation (e.g., ).
- **Class III**: Block in gating/regulation (e.g., ).
- **Class IV**: Reduced channel conductance (e.g., ).
- **Class V**: Reduced synthesis (e.g., ).
- **Class VI**: Accelerated turnover / membrane instability (e.g., ).
Diagnostic Testing for Cystic Fibrosis

New Zealand Newborn Screening ():
Tier 1: Immunoreactive Trypsinogen () from bloodspot. Top proceeds to Tier 2.
Tier 2: Targeted mutation panel covering exon 10/11 variants (, , ).
Diagnostic Sweat Chloride Thresholds:
: Unlikely (if 1 variant found: carrier).
: Inconclusive ( if 2 variants present with unclear consequences).
: Confirms (requires two variants in trans).
Molecular Testing Methods:

- ****: Allele-specific using terminal matching for targeted known variants.
- **Targeted **: Detects , small , and splice variants; ineffective for large or deep intronic regions.

- ****: Detects single/multi-exon deletions and duplications (). Normalized ratio (normal), (heterozygous deletion), (heterozygous duplication), (homozygous deletion).
Testing Strategies Across Monogenic Disorders

Familial Hypercholesterolemia (): , , — Targeted panel + .
Autosomal Dominant Polycystic Kidney Disease (): , — Specialised panel with custom long-range / capture + deletion/duplication analysis.
Neurofibromatosis Type 1 (): — Sequencing + .
Sickle Cell Disease (): (, ) — Targeted allele-specific genotyping or Sanger/ sequencing.
Tay-Sachs Disease: — Enzyme activity assay followed by targeted sequencing.
Phenylketonuria (): — Biochemical newborn screening () followed by sequencing.
Duchenne Muscular Dystrophy (): — first (large exon deletions/duplications), then sequencing if negative.
Repeat Expansion Disorders & Huntington Disease

Tandem DNA Repeats:
Satellite DNA: Hundreds of kb to Mb arrays in centromeres/heterochromatin.
Minisatellites (): repeat units.
Microsatellites (): repeat units. Expansions beyond thresholds cause disease.
Mechanisms of Expansion:

- **Unequal Crossing-Over**: Misalignment during meiotic recombination.
- **Replication Slippage**: Polymerase pausing and hairpin/loop formation during DNA synthesis.
Genetic Anticipation: Increase in severity or decrease in age-of-onset in successive generations due to meiotic repeat instability.
Huntington Disease ():
Genetics & Pathophysiology: Autosomal dominant expansion of repeat in Exon 1 of (), producing an N-terminal polyglutamine () tract that misfolds, aggregates, and causes striatal neurodegeneration.

Repeat Thresholds:
- </= 26: Normal.
- 27-35: Intermediate (unaffected, unstable in transmission).
- 36-39: Reduced penetrance.
- >/=40: Fully penetrant.
- Laboratory Diagnosis: Flanking PCR followed by capillary electrophoresis fragment analysis.
Comparative Trinucleotide Repeat Disorders
Huntington Disease (): in coding region polyQ misfolding & toxic gain-of-function.
Fragile X Syndrome (): in hypermethylation and gene silencing.
Myotonic Dystrophy Type 1 (): in toxic RNA foci and splicing factor sequestration.
Friedreich Ataxia (): in Intron 1 heterochromatin formation and frataxin deficiency.